<?xml version="1.0" encoding="ASCII"?>
<biogps><data><item key="platform">4</item><item key="owner">ArrayExpress Uploader</item><item key="pop_total">0</item><item key="species">human</item><item key="factors"><item><item key="GSE12251GSM307886"><item key="clinical information">response to Infliximab treatment</item></item></item><item><item key="GSE12251GSM307887"><item key="clinical information">no response to Infliximab</item></item></item><item><item key="GSE12251GSM307886"><item key="clinical information">response to Infliximab treatment</item></item></item><item><item key="GSE12251GSM307886"><item key="clinical information">response to Infliximab treatment</item></item></item><item><item key="GSE12251GSM307886"><item key="clinical information">response to Infliximab treatment</item></item></item><item><item key="GSE12251GSM307887"><item key="clinical information">no response to Infliximab</item></item></item><item><item key="GSE12251GSM307887"><item key="clinical information">no response to Infliximab</item></item></item><item><item key="GSE12251GSM307887"><item key="clinical information">no response to Infliximab</item></item></item><item><item key="GSE12251GSM307886"><item key="clinical information">response to Infliximab treatment</item></item></item><item><item key="GSE12251GSM307886"><item key="clinical information">response to Infliximab treatment</item></item></item><item><item key="GSE12251GSM307886"><item key="clinical information">response to Infliximab treatment</item></item></item><item><item key="GSE12251GSM307886"><item key="clinical information">response to Infliximab treatment</item></item></item><item><item key="GSE12251GSM307887"><item key="clinical information">no response to Infliximab</item></item></item><item><item key="GSE12251GSM307886"><item key="clinical information">response to Infliximab treatment</item></item></item><item><item key="GSE12251GSM307886"><item key="clinical information">response to Infliximab treatment</item></item></item><item><item key="GSE12251GSM307887"><item key="clinical information">no response to Infliximab</item></item></item><item><item key="GSE12251GSM307887"><item key="clinical information">no response to Infliximab</item></item></item><item><item key="GSE12251GSM307887"><item key="clinical information">no response to Infliximab</item></item></item><item><item key="GSE12251GSM307887"><item key="clinical information">no response to Infliximab</item></item></item><item><item key="GSE12251GSM307887"><item key="clinical information">no response to Infliximab</item></item></item><item><item key="GSE12251GSM307886"><item key="clinical information">response to Infliximab treatment</item></item></item><item><item key="GSE12251GSM307886"><item key="clinical information">response to Infliximab treatment</item></item></item><item><item key="GSE12251GSM307887"><item key="clinical information">no response to Infliximab</item></item></item></item><item key="id">2980</item><item key="ownerprofile_id">arrayexpress_sid</item><item key="source">http://www.ebi.ac.uk/arrayexpress/experiments/E-GEOD-12251</item><item key="summary_wrapped">Infliximab, an anti-TNFa monoclonal antibody, is an effective treatment for ulcerative colitis (UC) inducing over 60% of patients to...</item><item key="pubmed_id">19700435</item><item key="owner_profile">/profile/8773/arrayexpressuploader</item><item key="factor_count">1</item><item key="sample_count">23</item><item key="tags"><item>colitis</item><item>ulcerative colitis</item></item><item key="lastmodified">Dec.12, 2014</item><item key="is_default">False</item><item key="geo_gds_id"/><item key="slug">transcription-profiling-by-array-of-human-ulcerati</item><item key="geo_id_plat">E-GEOD-12251_A-AFFY-44</item><item key="name">Transcription profiling by array of human ulcerative colitis samples with varying responses to infliximab</item><item key="created">Sep.10, 2014</item><item key="summary">Infliximab, an anti-TNFa monoclonal antibody, is an effective treatment for ulcerative colitis (UC) inducing over 60% of patients to respond to treatment. Consequently, about 40% of patients do not respond. This study analyzed mucosal gene expression from patients enrolled in ACT1 to provide a predictive response signature for infliximab treatment. Experiment Overall Design: Twenty-two patients underwent colonoscopy with biopsy before infliximab treatment. Response to infliximab was defined as endoscopic and histologic healing at week 8 (P2, 5, 9, 10, 14, 15, 16, 17, 24, 27, 36, and 45 as responders; P3, 12, 13, 19, 28, 29, 32, 33, 34, and 47 as non-responders). Messenger RNA was isolated from pre-infliximab biopsies, labeled and hybridized to Affymetrix HGU133Plus_2.0 Array. The predictive response signature was verified by an independent data set.</item><item key="geo_gse_id">E-GEOD-12251</item><item key="sample_source">http://www.ebi.ac.uk/arrayexpress/experiments/E-GEOD-12251/samples/</item></data></biogps>
